drugset / Trial / NCT01835314

Compassionate Use of Stiripentol in Dravet Syndrome

NCT01835314

Expanded access No longer available University of Colorado, Denver

Summary

Compassionate use of Stiripentol in Dravet Syndrome. This is a treatment protocol, not a research study, therefore children will only be monitored on a clinical basis for seizure improvement predominantly by parent and caregiver report.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Stiripentol Small molecule 5 mg/kg Oral
Subject Stiripentol Small molecule 50 mg/kg Oral

Indications